Opendata, web and dolomites

DERMADROP

DERMADROP - A COMPREHENSIVE TRANSDERMAL THERAPY CONCEPT FOR NON- HEALING WOUNDS AND OTHER SKIN DISORDERS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "DERMADROP" data sheet

The following table provides information about the project.

Coordinator
MEDDROP GMBH 

Organization address
address: WILHEIM STEIN WEG 5
city: HAMBURG
postcode: 22339
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.dermadrop.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2015-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDDROP GMBH DE (HAMBURG) coordinator 50˙000.00

Map

 Project objective

TDA is an unprecedented drug delivery technology developed and patented by Meddrop GmbH. This technology platform is capable of targeted delivery of active substances effectively and non-invasively. TDA transports a combination of both, oxygen and drugs through all skin layers. These results and that of a series of wound treatments on diabetic wound patients prove that TDA has a huge potential in many areas, including the healing process on deep and chronic non-healing wounds as therapeutic modality. Wound healing will be the primary target application of DERMADROP, a therapy concept based on TDA. DERMADROP’s secondary applications are related to skin diseases and disorders such as psoriasis, acne, stretch marks, inflammation and its tertiary application is in the aesthetic medicine. The objective is to comercialise DERMADROP as a multipurpose medical concept to be used in hospitals and clinics all around the world primarily as a therapeutic modality for non-healing wounds and for the secondary applications mentioned above. It offers a comprehensive therapeutic modality that covers all aspect of wound management and treatment from debridement to wound closure. Wound closure is also expected to be comparatively shorter than currently available modalities. Apart from the fact that current treatment modalities are time consuming and costly, the result is often not effective. DERMADROP is a comprehensive therapeutic approach for non-healing wounds with reasonable costs for healthcare providers and insurance bodies. It is affordable for patients and efficient in its results. Others medical advantages include comfort for patients and user-friendliness. The multi-functionality of DERMADROP would be an added value that complements it as a highly competitive therapy solution, marketed by Meddrop GmbH and its existing extensive international distribution network.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DERMADROP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DERMADROP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More